|
[Related PubMed/MEDLINE]
Total Number of Papers: 74
|
|
|
|
|
[Display Entries]
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
|
Page: of
|
|
|
|
| Abbreviation |
: R-ISS |
| Long Form |
: Revised International Staging System |
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2023 |
A prognostic model incorporating inflammatory cells and cytokines for newly diagnosed multiple myeloma patients. |
IL-10, IL-1beta, IL-2R, IL-6, IL-8, ISS, LASSO, LMR, MM, NLR, PLR, SIRI, TNF-alpha |
| 2 |
2023 |
Experts' consensus on the definition and management of high risk multiple myeloma. |
EMN, HR, HRMM, MM |
| 3 |
2023 |
The prognostic utility of dynamic risk stratification at disease progression in patients with multiple myeloma. |
ISS, MM, mPPS |
| 4 |
2022 |
A stratified therapeutic model incorporated with studies on regulatory B cells for elderly patients with newly diagnosed multiple myeloma. |
Bd, CEMM2021, MM, NDMM, OS, PFS, PR |
| 5 |
2022 |
Amp 1q21 is more predictable with dismal survival than gain 1q21 of newly diagnosed multiple myeloma in real-world analysis. |
amp, FISH, HRCA, MM, NDMM, ORR, OS, PFS |
| 6 |
2022 |
Characteristics and clinical outcome of high-risk multiple myeloma patients in Korea (KMM 1805). |
KMR, MM, OS, PFS |
| 7 |
2022 |
Diagnosis and treatment of multiple myeloma in Hunan Province. |
DS, HQR, ISS, MM, NDMM, ORR |
| 8 |
2022 |
Different expression patterns of VISTA concurrent with PD-1, Tim-3, and TIGIT on T cell subsets in peripheral blood and bone marrow from patients with multiple myeloma. |
beta2-MG, BM, ECOG, HIs, MM, PB, PD-1, TIGIT, Tim-3, Treg, VISTA |
| 9 |
2022 |
Exploring the R-ISS stage-specific regular networks in the progression of multiple myeloma at single-cell resolution. |
MM |
| 10 |
2022 |
Heterogeneity in long term outcomes for R-ISS stage II in newly diagnosed multiple myeloma patients. |
CA |
| 11 |
2022 |
Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation. |
CI, HR, Isa, MM, PFS, RRMM, TEAEs |
| 12 |
2022 |
Myocardial Injury in Multiple Myeloma Patients With Preserved Left Ventricular Ejection Fraction: Noninvasive Left Ventricular Pressure-Strain Myocardial Work. |
AUC, CAEs, GLS, GWE, GWI, LVEF, LVMW, LVMWE, LVMWI, MM |
| 13 |
2022 |
Relation of whole-body metabolic tumor volume and total lesion glycolysis on fluorodeoxyglucose PET/computed tomography with clinical and laboratory parameters in newly diagnosed multiple myeloma. |
BM, MM, TLG, WBMTV |
| 14 |
2022 |
Revised International Staging System (R-ISS) stage-dependent analysis uncovers oncogenes and potential immunotherapeutic targets in multiple myeloma (MM). |
EBV, MM, PC, RRM2 |
| 15 |
2022 |
Risk Stratification Before and During Treatment in Newly Diagnosed Multiple Myeloma: From Clinical Trials to the Real-World Setting. |
MM, MRD, ND |
| 16 |
2022 |
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project. |
EMN, NDMM, OS, PFS |
| 17 |
2022 |
The applicability of the Second Revision of the International Staging System for patients with multiple myeloma receiving immunomodulatory drugs or proteasome inhibitor-based regimens as induction treatment: A real-world analysis. |
OS, PFS |
| 18 |
2022 |
The level and integrity of plasma circulating cell-free DNA in patients with primary multiple myeloma. |
cfDNA, DS, ISS, MM, PFS, qPCR, VGPR |
| 19 |
2022 |
Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group. |
ISS, MM |
| 20 |
2021 |
A prognostic survival model based on metabolism-related gene expression in plasma cell myeloma. |
PCM |
| 21 |
2021 |
Correlations between apparent diffusion coefficient values of WB-DWI and clinical parameters in multiple myeloma. |
ADC, beta2-MG, MM, WB-DWI |
| 22 |
2021 |
Current Approach to Managing Patients with Newly Diagnosed High-Risk Multiple Myeloma. |
DRD, mAb, MRD, PI |
| 23 |
2021 |
Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and 18F-FDG PET/CT. |
18F-FDG, FL, MM, NDMM, PET/CT |
| 24 |
2021 |
Evaluation of prognostic staging systems of multiple myeloma in the era of novel agents. |
Hgb, MM, OS |
| 25 |
2021 |
Favorable Long-Term Outcomes with Autologous Stem Cell Transplantation for High-Risk Multiple Myeloma Patients with a Positive Result On 18F-FDG PET/CT at Baseline. |
ASCT, EMD, FL, HDT, NDMM, OS, PFS |
| 26 |
2021 |
Histogram Analysis Based on Apparent Diffusion Coefficient Maps of Bone Marrow in Multiple Myeloma: An Independent Predictor for High-risk Patients Classified by the Revised International Staging System. |
ADC, DI, NDMM, OR, ROC, SD |
| 27 |
2021 |
Multiple Extramedullary-Bone Related and/or Extramedullary Extraosseous Are Independent Poor Prognostic Factors in Patients With Newly Diagnosed Multiple Myeloma. |
EM, EMB, EME, EMM, MM, OS, PFS |
| 28 |
2021 |
Prognostic value of circulating clonal plasma cells in newly diagnosed multiple myeloma. |
CPC, MM |
| 29 |
2021 |
Propensity-score matched analysis of the efficacy of maintenance/continuous therapy in newly diagnosed patients with multiple myeloma: a multicenter retrospective collaborative study of the Japanese Society of Myeloma. |
MM, OS, PFS |
| 30 |
2021 |
Role of whole-body diffusion-weighted imaging in evaluation of multiple myeloma. |
ADC, MM, WB-DWI |
| 31 |
2021 |
The association of mobilising regimen on immune reconstitution and survival in myeloma patients treated with bortezomib, cyclophosphamide and dexamethasone induction followed by a melphalan autograft. |
CY, OS, TTNT |
| 32 |
2021 |
The detection of circulating plasma cells may improve the Revised International Staging System (R-ISS) risk stratification of patients with newly diagnosed multiple myeloma. |
CPCs, LDH, MM, OS, PFS |
| 33 |
2021 |
[Analysis of the clinical effects and outcome of patients with double-hit high-risk multiple myeloma]. |
MM, OS, PFS, RVD |
| 34 |
2021 |
[Predictive Value of Newly Diagnosed IgG Level in Patients with IgG-type Multiple Myeloma after Initial Treatment]. |
ASCT, BMPC, LDH, MM |
| 35 |
2020 |
18F-FDG and 11C-Methionine PET/CT in Newly Diagnosed Multiple Myeloma Patients: Comparison of Volume-Based PET Biomarkers. |
11C-MET, 18F-FDG, B2M, FL, FLC, LDH, MM, PET, SUV, TLG, TMTV |
| 36 |
2020 |
A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. |
MM, ND, OS, PFS, PI |
| 37 |
2020 |
A Tangle of Genomic Aberrations Drives Multiple Myeloma and Correlates with Clinical Aggressiveness of the Disease: A Comprehensive Review from a Biological Perspective to Clinical Trial Results. |
MM |
| 38 |
2020 |
Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents. |
C1As, HRCAs, MM, OS |
| 39 |
2020 |
Circulating miR-451a levels as a potential biomarker to predict the prognosis of patients with multiple myeloma. |
BM, IL-6R, MFC, MM, MRD |
| 40 |
2020 |
Cytogenetics and Revised International Staging System (R-ISS): Risk Stratification in Multiple myeloma - A Retrospective Study in Indian Population. |
FISH, iFISH, MM |
| 41 |
2020 |
Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. |
HR, MM, OS, PFS |
| 42 |
2020 |
Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. |
FISH, MM, OS, PCPro, PFS |
| 43 |
2020 |
miR-451a suppression of IL-6R can inhibit proliferation and increase apoptosis through the JAK2/STAT3 pathway in multiple myeloma. |
BM, IL-6, MM |
| 44 |
2020 |
Multiple Myeloma in Hispanics: Incidence, Characteristics, Survival, Results of Discovery, and Validation Using Real-World and Connect MM Registry Data. |
MM, NHB, NHW |
| 45 |
2020 |
NUPR1 Silencing Induces Autophagy-Mediated Apoptosis in Multiple Myeloma Cells Through the PI3K/AKT/mTOR Pathway. |
DS, MM, NUPR1 |
| 46 |
2020 |
Prognostic and predictive performance of R-ISS with SKY92 in older patients with multiple myeloma: the HOVON-87/NMSG-18 trial. |
HR, MM, MPT-T, OS, SR |
| 47 |
2020 |
Serum-free light chains combined with the Revised International Staging System could further distinguish the superior and inferior clinical outcome of multiple myeloma patients. |
MM, MR-ISS, NDMM, sFLC |
| 48 |
2019 |
Clinical characteristics and prognosis of immunoglobulin D myeloma in the novel agent era. |
FISH, IgD |
| 49 |
2019 |
Evaluation of the Revised International Staging System (R-ISS) in Japanese patients with multiple myeloma. |
OS |
| 50 |
2019 |
High Expression Levels of Long Noncoding RNA Small Nucleolar RNA Host Gene 18 and Semaphorin 5A Indicate Poor Prognosis in Multiple Myeloma. |
DS, ISS, MM, OS, SNHG18 |
| 51 |
2019 |
Improved survival outcomes and relative youthfulness of multiple myeloma patients with t(4;14) receiving novel agents are associated with poorer performance of the revised international staging system in a real aging society. |
MM, OS |
| 52 |
2019 |
Next Generation Sequencing-based Validation of the Revised International Staging System for Multiple Myeloma: An Analysis of the MMRF CoMMpass Study. |
CAs, FISH, MMRF, NGS, R-ISS-NGS |
| 53 |
2019 |
Role of Conventional Karyotyping in Multiple Myeloma in the Era of Modern Treatment and FISH Analysis. |
HR, OS |
| 54 |
2019 |
[A Patient Surviving More Than Five Years Due to the Effect of Sequential Alternating Chemotherapy Administered to Metachronous Overlapping Cancer of Multiple Myeloma and StageⅣ EGFR Positive Non-Small Cell Lung Cancer]. |
aPBSCT, CR, GEF, PD |
| 55 |
2018 |
18F-FDG PET/CT is useful for determining survival outcomes of patients with multiple myeloma classified as stage II and III with the Revised International Staging System. |
EMD, FLs, MM, OS, PFS |
| 56 |
2018 |
Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients. |
ASCT, CA, MM, OS |
| 57 |
2018 |
Nucleic acid based risk assessment and staging for clinical practice in multiple myeloma. |
CA, FISH, LDH, MLPA, MM, OS, PFS, qRT-PCR |
| 58 |
2018 |
Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. |
AHCT, MM, OS, PFS |
| 59 |
2018 |
Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. |
AHCT, CI, IMWG 2014, MM, OS |
| 60 |
2018 |
Successful Use of Intravenous Immunoglobulin G to Treat Refractory Heparin-Induced Thrombocytopenia With Thrombosis Complicating Peripheral Blood Stem Cell Harvest. |
--- |
| 61 |
2018 |
The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. |
FLs, GEP, MM, OS, PFS |
| 62 |
2018 |
The Role of 18F-FDG PET/CT in Multiple Myeloma Staging according to IMPeTUs: Comparison of the Durie-Salmon Plus and Other Staging Systems. |
DS Plus, DSS, IMPeTUs, MM, OS |
| 63 |
2018 |
Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies. |
IMWG, MM, OS |
| 64 |
2017 |
Automatic digital quantification of bone marrow myeloma volume in appendicular skeletons - clinical implications and prognostic significance. |
MDCT, MM |
| 65 |
2017 |
Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma. |
NDMM, OS, PFS, RRMM |
| 66 |
2017 |
Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy. |
CI, MM, OS |
| 67 |
2017 |
High serum lactate dehydrogenase predicts an unfavorable outcome in Chinese elderly patients with multiple myeloma. |
LDH, MM, ORR, OS, PFS |
| 68 |
2017 |
The Revised International Staging System Compared to the Classical International Staging System Better Discriminates Risk Groups among Transplant-Ineligible Multiple Myeloma Patients. |
ISS, MM, OS |
| 69 |
2017 |
[Outcomes of lenalidomide-based treatment for 57 patients of relapsed or refractory multiple myeloma]. |
AEs, CR, DOR, ISS, MM, MR, ORR, OS, PFS, PR, VGPR |
| 70 |
2017 |
[Prognostic value of the revised international staging system for newly diagnosed multiple myeloma patients]. |
MM |
| 71 |
2016 |
Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma. |
--- |
| 72 |
2016 |
Revised International Staging System Applied to Real World Multiple Myeloma Patients. |
ISS |
| 73 |
2016 |
Risk Stratification in Multiple Myeloma. |
ISS |
| 74 |
2016 |
[Analysis of serum free light chains kappa/lamda ratio and heavy/light chain pairs of immunoglobulin to the stratification of multiple myeloma according to Mayo Stratification of Myeloma and Revised International Staging System]. |
DS, ISS, MM, mSMART |
|
A Search Service for Abbreviation / Long Form
